You are now viewing 1 - 10 of 64 results
November 20, 2007 | Program Results Report
The Partnership for Prevention conducted a series of surveys and focus groups with employers to determine to what extent employer-sponsored health insurance plans offer coverage for clinical preventive services or promote their use.
November 16, 2012 | Program Results Report
For two decades Join Together served as a national resource center for local substance abuse initiatives, and promoted policies that enhance prevention and treatment. The Partnership at Drugfree.org is now the portal for these resources.
November 12, 2012 | Report
In this statement presented by 25 national health organizations, a set of principles are presented which represent their commitment to conserving and replenishing antibiotic resources.
April 10, 2012 | Program Results Report
Oral Health America, a Chicago-based organization that advocates improved dental care, launched a public education campaign to reduce the use of spit tobacco (both chewing tobacco and snuff).
January 1, 2012 | Journal Article
When patients are likely to develop immunity to infection, the duration of antibiotic treatments can be shortened without harm, thus delaying the spread of drug resistance and its concomitant public health impacts, according to this model-based analysis.
November 15, 2011 | Story
RWJF-funded Extending the Cure releases new research showing troubling trends in antibiotic use.
November 14, 2011 | Journal Article
Index developed to quantify changes in drug resistance over time.
November 14, 2011 | Journal Article
Index developed to quantify changes in drug resistance over time.
October 4, 2011 | Program Results Report
Beginning in 2002, the MTCT-Plus Initiative established family-based HIV care and treatment programs in sub-Saharan Africa and Thailand, linking HIV care and treatment of mothers to existing programs that prevent mother-to-child transmission of HIV.
October 1, 2011 | Journal Article
This study suggests that government incentives are needed to encourage the research and development that goes into producing novel antibiotics, in addition to increasing development of new ones.